Global Neutropenia Treatment Market 2017-2021

Gglobal neutropenia treatment market overview

Technavio’s market research report predicts that the global neutropenia treatment market will grow at a CAGR of above 4% during the forecast period. Novel therapies combined with growing cases of chemotherapy-induced neutropenia is one of the primary drivers for market growth. Novel products such as Taiho’s drugs, ZOSYN 2.25, ZOSYN 4.5, and ZOSYN 4.5 for I.V. infusion bag, are in the pipeline and have received marketing approval for the treatment of febrile neutropenia in Japan in 2015. These products are anticipated to revolutionize the global market and the initiatives of the key vendors to increase the awareness about these novel mechanisms among healthcare experts will also strength fuel its growth. Moreover, the novel drug delivery technique also improves patient convenience leading to better patient adherence thus driving the market growth. For instance, Amgen launched Neulasta Onpro kit, a novel drug delivery mechanism that allows self-administration of Neulasta. Furthermore, since cancer is the known cause for developing neutropenia, the increasing cases of chemotherapy for the treatment of cancer will be a growth driver for the neutropenia treatment market.

Get A Free Sample